Moderna
Trade Moderna 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About MRNA
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics.
MRNA Key Statistics
MRNA News
Moderna (MRNA) ended the recent trading session at $27.54, demonstrating a +2.53% change from the preceding day's closing price. The stock's performance was ahe...
Mixed options sentiment in Moderna (MRNA), with shares up 33c, or 1.26%, near $26.58. Options volume running well above average with 93k contracts traded and ca...
Investors in Moderna Inc (Symbol: MRNA) saw new options begin trading today, for the December 5th expiration. At Stock Options Channel , our YieldBoost formula...
Analyst ratings
59%
of 27 ratingsMore MRNA News
Moderna, Inc. (NASDAQ:MRNA) revealed topline results on Wednesday from a Phase 3 trial evaluating the efficacy of mRNA-1647, the company’s investigational cytom...
Moderna (MRNA) stock toppled Thursday after the biotech company's experimental CMV vaccine failed in a Phase 3 study of 7,500 women. The study's goal was to pr...
Moderna, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst David Dai from UBS maintained a Buy rating on the stock and has a...
Valued at $10.7 billion by market cap, Moderna, Inc. (MRNA) is a biotechnology company specializing in the development and commercialization of messenger RNA (m...
Moderna drops after reporting trial for birth defect vaccine failed Moderna dropped in after hours trading after it reported on Wednesday that its experimental...
Moderna (NASDAQ:MRNA) announced that its late-stage trial for the mRNA-1647 vaccine, aimed at preventing cytomegalovirus infection, did not achieve its primary...
The biotech's innovative qualities will come in handy. Long gone are the days when Moderna (MRNA 3.56%) would generate over $18 billion in annual sales from it...
